Kalaokalani Chandler, MD
Obstetrics/Gynecology · Castro Valley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 15
- 4 carriers
- Offices
- 3
- Since medical school
- 27 years
- Washington University School of Medicine, 1999
Offices
3 locations · University Healthcare Alliance · 334 clinicians in this group
Hospitals listed: Eden Medical Center · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
15 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chandler’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
15 of 15 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A73204 · Current
Licensed to practise in California · since 2000 · expires 2028-07-31 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Bay Valley Medical Group, Inc.Hayward, CA10% owner since 1972 · accredited by IMQAccreditation Renewed1 inspection · last 2011-09-02
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$27,312
Medicare paid this office $27,312 for 120 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 45 | $5,480 | $74 |
| Return visit (30+ min) | 22 | $2,443 | $106 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 37 | $1,754 | $47 |
| Fitting and insertion of vaginal support device | 14 | $1,002 | $59 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $680 | $57 |
See all 6 services
| Short return visit (20+ min) | 45 | $5,480 | $74 |
| Return visit (30+ min) | 22 | $2,443 | $106 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 37 | $1,754 | $47 |
| Fitting and insertion of vaginal support device | 14 | $1,002 | $59 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $680 | $57 |
| Short return visit | 11 | $498 | $45 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Fitting and insertion of vaginal support device | – | – | – | – | – | 17 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
120 Original Medicare patients in 2024. Average age 72 · Under 65 11% · 85 and older 9% · Women 100% · Also on Medicaid 26% · Health risk score 0.89. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 63% · Diabetes 29% · Depression 19% · Coronary heart disease 16% · Chronic kidney disease 15% · Cancer 11% · Heart failure 9% · Stroke 9%.
The office billed $144,396, Medicare allowed $37,110 and paid $27,312; for 413 services of 34 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 120 | 413 | 72 | 0.89 | $144,396 | $27,312 |
| 2023 | 124 | 269 | 69 | 1.02 | $97,887 | $21,848 |
| 2022 | 95 | 182 | 73 | 1.00 | $67,866 | $15,370 |
| 2021 | 117 | 250 | 71 | 1.10 | $91,161 | $19,319 |
| 2020 | 95 | 217 | 72 | 1.20 | $80,577 | $14,159 |
| 2019 | 116 | 249 | 72 | 1.14 | $109,671 | $21,977 |
| 2018 | 110 | 204 | 70 | 1.02 | $85,649 | $18,425 |
| 2017 | 97 | 172 | 71 | 1.00 | $60,219 | $13,801 |
| 2016 | 85 | 144 | 72 | 1.05 | $56,835 | $11,184 |
| 2015 | 86 | 156 | 71 | 1.04 | $49,131 | $10,149 |
| 2014 | 90 | 351 | 70 | 1.03 | $55,347 | $12,227 |
| 2013 | 98 | 211 | 68 | 1.12 | $45,220 | $12,597 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Short return visit (20+ min) | 36 | $4,618 | $80 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 64 | $3,000 | $47 |
| Return visit (30+ min) | 24 | $2,813 | $100 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 14 | $765 | $55 |
| Short return visit | 11 | $705 | $50 |
2022: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 52 | $2,413 | $46 |
| Short return visit (20+ min) | 16 | $1,366 | $72 |
| Return visit (30+ min) | 11 | $1,226 | $102 |
| Short return visit | 12 | $765 | $40 |
2021: 5 services
| Short return visit (20+ min) | 31 | $3,061 | $78 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 57 | $2,724 | $48 |
| Short return visit | 18 | $979 | $45 |
| New patient visit (30+ min) | 12 | $965 | $80 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 14 | $767 | $55 |
2020: 4 services
| Short return visit (20+ min) | 24 | $2,458 | $61 |
| Return visit (30+ min) | 22 | $2,403 | $96 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 45 | $2,157 | $48 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $653 | $54 |
2019: 5 services
| Short return visit (20+ min) | 37 | $2,894 | $60 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 56 | $2,602 | $46 |
| New patient visit (30+ min) | 13 | $1,244 | $96 |
| Return visit (30+ min) | 13 | $1,049 | $75 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $702 | $54 |
2018: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 54 | $2,426 | $45 |
| Short return visit (20+ min) | 27 | $2,242 | $61 |
| Return visit (30+ min) | 14 | $1,333 | $95 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $598 | $54 |
2017: 4 services
| Short return visit (20+ min) | 30 | $2,148 | $65 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 33 | $1,469 | $45 |
| Short return visit | 16 | $856 | $34 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $697 | $54 |
2016: 3 services
| Short return visit | 28 | $1,743 | $32 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 37 | $1,598 | $43 |
| Short return visit (20+ min) | 13 | $889 | $59 |
2015: 3 services
| Short return visit (20+ min) | 23 | $1,801 | $56 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 36 | $1,541 | $43 |
| Short return visit | 25 | $1,386 | $31 |
2014: 4 services
| Short return visit (20+ min) | 25 | $2,204 | $58 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 36 | $1,543 | $43 |
| Short return visit | 21 | $1,382 | $36 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 15 | $777 | $52 |
2013: 4 services
| Short return visit (20+ min) | 27 | $2,317 | $58 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 44 | $1,909 | $43 |
| Short return visit | 25 | $1,540 | $33 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 25 | $1,341 | $54 |
Medicaid work
$223 in 2024
Medicaid paid $223 for 31 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 31 | $223 |
| 2024 | 31 | 1 | 14 | $223 |
| 2018 | 12 | 1 | 12 | $299 |
See the largest Medicaid services in earlier years
2018
| Short return visit (20+ min) | 12 | $299 |
Drugs they prescribed that Part D paid
$38,782
Pharmacies billed $38,782 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (25 of 359) in 2024. A higher opioid share than 9 in 10 peers; the typical obstetrics & gynecology clinician is at 0%.
275 generic and fewer than 11 brand-name prescriptions · $38,782 in drug cost · 17 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Premarin | 26 | $12,031 | $463 |
| Estradiol | 75 | $3,666 | $49 |
| Estradiol (Twice Weekly) | 12 | $833 | $69 |
| Clobetasol Propionate | 16 | $493 | $31 |
| Medroxyprogesterone Acetate | 29 | $345 | $12 |
See all 7 drugs
| Premarin | 26 | $12,031 | $463 |
| Estradiol | 75 | $3,666 | $49 |
| Estradiol (Twice Weekly) | 12 | $833 | $69 |
| Clobetasol Propionate | 16 | $493 | $31 |
| Medroxyprogesterone Acetate | 29 | $345 | $12 |
| Acyclovir | 12 | $200 | $17 |
| Oxycodone | 15 | $128 | $9 |
Year by year
| 2024 | 359 | 116 | 7% (25) | None | $38,782 |
| 2023 | 334 | 100 | 6% (21) | 19% | $34,244 |
| 2022 | 232 | 77 | 13% (30) | 20% | $26,950 |
| 2021 | 371 | 83 | 23% (84) | 18% | $33,442 |
| 2020 | 299 | 67 | 14% (42) | 29% | $33,089 |
| 2019 | 228 | 72 | None | 21% | $25,317 |
| 2018 | 276 | 79 | 5% (13) | 13% | $17,690 |
| 2017 | 231 | 79 | 5% (12) | None | $22,056 |
| 2016 | 226 | 61 | None | 22% | $19,460 |
| 2015 | 171 | 54 | None | 25% | $15,516 |
| 2014 | 154 | 59 | None | 39% | $14,322 |
| 2013 | 165 | 60 | 10% (16) | 35% | $15,296 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Premarin | 16 | $8,022 | $501 |
| Yuvafem | 12 | $2,475 | $206 |
| Tolterodine Tartrate Er | 11 | $2,016 | $183 |
| Clobetasol Propionate | 25 | $1,361 | $54 |
| Estradiol | 31 | $1,301 | $42 |
| Valacyclovir | 14 | $1,297 | $93 |
| Oxybutynin Chloride Er | 20 | $478 | $24 |
| Oxycodone | 15 | $398 | $27 |
| Medroxyprogesterone Acetate | 23 | $307 | $13 |
| Acyclovir | 11 | $280 | $25 |
| Terconazole | 12 | $275 | $23 |
| Fluconazole | 19 | $103 | $5 |
| Triamcinolone Acetonide | 11 | $67 | $6 |
| Ciprofloxacin | 12 | $58 | $5 |
2022: 7 drugs
| Premarin | 15 | $7,063 | $471 |
| Valacyclovir | 15 | $966 | $64 |
| Estradiol | 21 | $959 | $46 |
| Oxycodone | 26 | $614 | $24 |
| Clobetasol Propionate | 12 | $464 | $39 |
| Acyclovir | 12 | $374 | $31 |
| Triamcinolone Acetonide | 19 | $83 | $4 |
2021: 10 drugs
| Prempro | 20 | $7,478 | $374 |
| Estradiol | 39 | $2,091 | $54 |
| Tolterodine Tartrate Er | 11 | $1,706 | $155 |
| Oxycodone | 53 | $1,628 | $31 |
| Estradiol (Once Weekly) | 17 | $1,104 | $65 |
| Clobetasol Propionate | 21 | $993 | $47 |
| Trospium Chloride | 13 | $557 | $43 |
| Morphine Sulfate Er | 26 | $371 | $14 |
| Acyclovir | 17 | $239 | $14 |
| Fluconazole | 13 | $74 | $6 |
2020: 9 drugs
| Prempro | 11 | $6,295 | $572 |
| Tolterodine Tartrate Er | 12 | $1,532 | $128 |
| Estradiol (Once Weekly) | 16 | $840 | $53 |
| Estradiol | 23 | $748 | $33 |
| Clobetasol Propionate | 16 | $487 | $30 |
| Medroxyprogesterone Acetate | 12 | $199 | $17 |
| Oxycodone-Acetaminophen | 18 | $115 | $6 |
| Triamcinolone Acetonide | 16 | $108 | $7 |
| Fluconazole | 13 | $79 | $6 |
2019: 3 drugs
| Estradiol | 52 | $3,775 | $73 |
| Tolterodine Tartrate Er | 12 | $2,056 | $171 |
| Clobetasol Propionate | 13 | $1,199 | $92 |
2018: 8 drugs
| Estradiol | 37 | $2,462 | $67 |
| Tolterodine Tartrate Er | 13 | $1,983 | $153 |
| Clobetasol Propionate | 12 | $1,289 | $107 |
| Norethindron-Ethinyl Estradiol | 12 | $653 | $54 |
| Oxybutynin Chloride Er | 14 | $634 | $45 |
| Medroxyprogesterone Acetate | 24 | $274 | $11 |
| Ibu | 13 | $81 | $6 |
| Ibuprofen | 12 | $63 | $5 |
2017: 8 drugs
| Tolterodine Tartrate Er | 16 | $4,492 | $281 |
| Estrace | 11 | $3,156 | $287 |
| Clobetasol Propionate | 19 | $2,077 | $109 |
| Yuvafem | 11 | $1,718 | $156 |
| Estradiol | 13 | $1,246 | $96 |
| Oxybutynin Chloride Er | 19 | $958 | $50 |
| Norethindron-Ethinyl Estradiol | 11 | $661 | $60 |
| Medroxyprogesterone Acetate | 21 | $218 | $10 |
2016: 7 drugs
| Clobetasol Propionate | 15 | $1,785 | $119 |
| Oxybutynin Chloride Er | 21 | $737 | $35 |
| Norethindron-Ethinyl Estradiol | 12 | $714 | $59 |
| Fluconazole | 21 | $299 | $14 |
| Estradiol | 12 | $161 | $13 |
| Alendronate | 12 | $120 | $10 |
| Metformin Hcl Er | 12 | $78 | $7 |
2015: 4 drugs
| Clobetasol Propionate | 21 | $3,001 | $143 |
| Trospium Chloride | 13 | $1,626 | $125 |
| Prempro | 12 | $1,602 | $134 |
| Oxybutynin Chloride Er | 15 | $501 | $33 |
2014: 3 drugs
| Premarin | 22 | $4,923 | $224 |
| Prempro | 13 | $1,477 | $114 |
| Clobetasol Propionate | 11 | $277 | $25 |
2013: 3 drugs
| Premarin | 20 | $4,021 | $201 |
| Prempro | 11 | $1,077 | $98 |
| Clobetasol Propionate | 11 | $232 | $21 |
Money from drug and device companies
$22 in 2025
| 2025 | 1 | 1 | None | $22 |
| 2022 | 1 | 1 | None | $96 |
| 2019 | 2 | 6 | None | $622 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| CooperSurgical | Paragard T 380a | $22 | 1 payment
|
See the published payment
| CooperSurgical | Meals · 2025-05-01 | Paragard T 380a | $22 |
See earlier years (2022, 2019)
2022: $96
| Abbvie | Orilissa | $96 | 1 payment
|
2019: $622
| Boston Scientific | General Female Sui | $444 | 4 payments
|
| AbbVie | Orilissa | $178 | 2 payments
|
Professional record
- NPI
- 1164459947
- Licence
- CA A73204California A73204: Current · expires 2028-07-31
- Trained
- Washington University School of Medicine, 1999 · 27 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 20642 John Dr, Castro Valley, CA, 94546
- NPI first listed
- 2006-06-27
- NPI last updated
- 2023-04-12
- NPI record certified
- 2023-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 27212 Calaroga Ave, Hayward, CA, 94545